TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03539601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crisaborole ointment, 2%
Description: Applied twice a day (BID)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone butyrate cream, 0.1%
Description: Applied BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pimecrolimus cream, 1%
Description: Applied BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Crisaborole Vehicle
Description: Applied BID
Study: NCT03671304

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit Versa
Description: Participants will receive a Fitbit Versa and instructions on its use. Participants will be asked to wear the device for eight weeks, removing it only for charging and when engaging in activities in which the device could be submerged in water (bathing, swimming, etc.).~At enrollment, participants will indicate a preferred time to receive affective framing messages and EMA prompts (morning), and intention planning prompts (evenings). Participants will receive affective framing messages and intention planning prompts on a randomized schedule, such that participants will receive each message type on 50% of days.
Study: NCT02584504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 5 mg tablet orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 5 mg tablet orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-statin Lipid-Modifying Therapy
Description: Ezetimibe, Bezafibrate or Fenofibrate at stable dose as background therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-statin Lipid-Modifying Therapy
Description: Ezetimibe, Bezafibrate or Fenofibrate at stable dose as background therapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Non-statin Lipid-Modifying Therapy
Description: Ezetimibe, Bezafibrate or Fenofibrate at stable dose as background therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet Alone
Description: Stable cholesterol-lowering diet as background therapy.
Study: NCT03874091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine PCA pump
Description: Morphine given postoperatively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine PCA pump
Description: Morphine given postoperatively.
Study: NCT01117532

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EFT (Emotional Freedom Techniques)
Description: Four 90 minute group therapy classes of this behavioral intervention
Study: NCT04271813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib plus Sintilimab
Description: Anlotinib 12mg oral administration daily d1-d14, q3w; Sintilimab 200mg iv drop d1, q3w
Study: NCT03145909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-176
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-176
Description: Intravenous infusion
Study: NCT04407442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV or PO
Study: NCT02907489

Intervention type: OTHER
Group type: OTHER
Intervention: triple antibiotic paste with an anti-inflammatory drug
Description: Mixture of ciprofloxacin, metronidazole and minocycline.and diclofenac potassium 50 mg (Catafast)
Study: NCT01783379

Intervention type: DRUG
Intervention: micafungin
Description: 100mg/day infusion in 1 hour
Study: NCT01151865

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine will be administered intravenously as a maintenance infusion of 0.2 to 1.5 mcg/kg/hour, commencing at 0.5 mcg/kg/hour and titrated according to effect, for as long as deemed necessary by the treating physician. Specifically, the study medication may be (as recommended by the manufacturer) continued after extubation, and if discontinued may be restarted at any time up until ICU discharge. The clinician will have the option of using a loading dose of 1.0 mcg/kg IV over 20 minutes, as recommended by the manufacturer.~Bedside nursing staff will adjust drug infusion rates as necessary, in consultation with the treating physician, aiming to achieve a Riker Sedation-Agitation Scale 20 score of 4.
Study: NCT02170870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exendin 9-39
Description: Exendin 9-39 will be administered intravenously (1,200 pmol/kg bolus followed by infusion at 300 pmol/kg/min).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exendin 9-39
Description: Exendin 9-39 will be administered intravenously (1,200 pmol/kg bolus followed by infusion at 300 pmol/kg/min).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exendin 9-39
Description: Exendin 9-39 will be administered intravenously (1,200 pmol/kg bolus followed by infusion at 300 pmol/kg/min).
Study: NCT01151865

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: An identical syringe containing only saline with no dexmedetomidine added will be supplied. Initial rate of infusion and subsequent adjustments will be the same as in the active comparator group.
Study: NCT02170870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microlipid
Description: Lipid infusion {66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Microlipid
Description: Lipid infusion {66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microlipid
Description: Lipid infusion {66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Microlipid
Description: Lipid infusion {66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microlipid
Description: Lipid infusion {66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml).
Study: NCT02584504

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet Alone
Description: Stable cholesterol-lowering diet as background therapy.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Diet Alone
Description: Stable cholesterol-lowering diet as background therapy.
Study: NCT00358202

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefepime
Description: cefepime hydrochloride 1gm IM q24h
Study: NCT02213666

Intervention type: DEVICE
Intervention: Intracardiac Imaging
Description: Imaging of the RAA and LAA with ICE and assessment of thrombus.
Study: NCT03763448

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infrapatellar Fat Pad preservation
Description: In the IPFP preservation group, IPFP (more than 80%) will be preserved by retracting out of the operative field.
Study: NCT02170870

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Microlipid
Description: Lipid infusion {66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline infusion will be prepared to match the appearance of Exendin 9-39

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline infusion will be prepared to match the appearance of Exendin 9-39
Study: NCT00358202

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ceftriaxone
Description: ceftriaxone 1 gm IM q24h
Study: NCT03483935

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microwave treatment
Description: Microwave energy delivered using the microwave instrument, SWIFT, manufactured by Emblation and CE marked for dermatology applications.
Study: NCT03621228

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MindfulGarden
Description: MindfulGarden (MG) is an interactive digital technology that combines use of a smart television with sensors to intelligently generate content based on patient voice and gesture input, triggering a multi-layered visual 'garden' on-screen to arrest and de-escalate anxiety and aggression in treatment of hospitalized elderly diagnosed with hyperactive delirium.
Study: NCT00294164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serostim®
Description: Serostim® will be administered subcutaneously (daily or given on alternate days with matched placebo), at a dose based on body weight measured at Baseline, with a maximum daily dose of 4 mg up to Week 24.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serostim®
Description: Serostim® will be administered subcutaneously (daily or given on alternate days with matched placebo), at a dose based on body weight measured at Baseline, with a maximum daily dose of 4 mg up to Week 24.
Study: NCT02170870

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline infusion will be prepared to match the appearance of Exendin 9-39
Study: NCT00294164

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered subcutaneously (daily or given on alternate days with Serostim®), up to Week 24.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered subcutaneously (daily or given on alternate days with Serostim®), up to Week 24.
Study: NCT02534831

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Soft tissue manual therapy protocol
Description: The STMTP consisted of a pre-determined set of seven (7) soft tissue techniques delivered as part of a single treatment session lasting approximately 30 minutes. The techniques and their respective durations were: suboccipital release (5 minutes), anterior thoracic myofascial and sternum release (5 minutes), anterior cervical myofascial release (5 minutes), costal ligament balance (5 minutes) and muscular energy technique (MET) to the following muscles - scalenes (1 minute and 40 seconds), pectoralis minor (1 minute and 40 seconds) and latissimus dorsi and serratus anterior (1 minute and 40 seconds)
Study: NCT00581074

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: diet (grapefruit or grapefruit juice)
Description: weight loss diet

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: diet (grapefruit or grapefruit juice)
Description: weight loss diet
Study: NCT03763448

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infrapatellar Fat Pad resection
Description: In the IPFP resection group, more than 80% IPFP will be resected during the total knee arthroplasty.
Study: NCT04337463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG-008
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: IV infusion
Study: NCT04620005

Intervention type: OTHER
Intervention: Observational
Description: Survey

Intervention type: OTHER
Intervention: Observational
Description: Survey
Study: NCT04087005

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hominis placental pharmacopuncture
Description: Hominis placental pharmacopuncture is human placental extract, which has been used in traditional Korean medicine to treat chronic diseases, including frailty, cough, anorexia, and fatigue, by enhancing the body's resistance.
Study: NCT00581074

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: diet (grapefruit or grapefruit juice)
Description: weight loss diet
Study: NCT04087005

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hominis placental pharmacopuncture
Description: Hominis placental pharmacopuncture is human placental extract, which has been used in traditional Korean medicine to treat chronic diseases, including frailty, cough, anorexia, and fatigue, by enhancing the body's resistance.
Study: NCT01128699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subconjunctival Avastin
Description: Intraoperative Subconjunctival Avastin 1.25mg; single dose as an adjunct to 184 mm2 surface area Ahmed Glaucoma Valve (AGV Model FP7; New World Medical Inc., Rancho Cucamonga, California, USA)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ahmed Valve implant
Description: 184 mm2 surface area Ahmed Glaucoma Valve (AGV Model FP7; New World Medical Inc., Rancho Cucamonga, California, USA)
Study: NCT02349100

Intervention type: DEVICE
Intervention: Nellix Endoprosthesis
Description: Implantation of Nellix
Study: NCT03714139

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immediate loading
Description: The participants will be assigned to immediate or delayed functional loading groups. In each participant, edentulous areas with adequate thickness of the alveolar bone crest will be identified and at least two sites will be identified for implant installation. All implant recipient sites will be sub-prepared to allow good stability of the implants. Experimental mini-implants (Sweden \& Martina, Due Carrare, Padova, Italy), 3.5 mm in diameter and with an intraosseous portion of 4 mm in length will be installed.~Immediate loading group - A prosthetic component will be applied over the trial implants. Impressions will be taken and a crown / bridge will be provided to patients in one day.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non implant loading
Description: Control implants will receive a healing screw and will remain unloaded
Study: NCT04114227

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acceptance and Commitment Therapy adapted for Cystic Fibrosis (ACT with CF)
Description: Subjects learn new ways to manage uncomfortable experiences and feelings and to engage in positive behaviors

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Psychotherapy (Treatment as Usual Control)
Description: Subjects talk about their experiences to date in a cohort of adult Cystic Fibrosis patients.
Study: NCT03588494

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: concurrent chemoradiotherapy (CCRT)
Description: Chemotherapy: Cisplatin (50 mg/m2) on days 1, 8, 29, and 36 and etoposide (50mg/m2) on days 1～5 and 29～33.~Radiotherapy: Thoracic radiotherapy (TRT) started with a linear accelerator (6MV-X) on the first day of chemotherapy.A minimum dose of 60 Gy (2 Gy per fraction, Monday～Friday) was delivered, and a range of 60-66 Gy in 2 Gy fractions was allowed.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: concurrent chemoradiotherapy (CCRT)
Description: Chemotherapy: Cisplatin (50 mg/m2) on days 1, 8, 29, and 36 and etoposide (50mg/m2) on days 1～5 and 29～33.~Radiotherapy: Thoracic radiotherapy (TRT) started with a linear accelerator (6MV-X) on the first day of chemotherapy.A minimum dose of 60 Gy (2 Gy per fraction, Monday～Friday) was delivered, and a range of 60-66 Gy in 2 Gy fractions was allowed.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: concurrent chemoradiotherapy (CCRT)
Description: Chemotherapy: Cisplatin (50 mg/m2) on days 1, 8, 29, and 36 and etoposide (50mg/m2) on days 1～5 and 29～33.~Radiotherapy: Thoracic radiotherapy (TRT) started with a linear accelerator (6MV-X) on the first day of chemotherapy.A minimum dose of 60 Gy (2 Gy per fraction, Monday～Friday) was delivered, and a range of 60-66 Gy in 2 Gy fractions was allowed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar for one cycle
Description: Endostar(15mg/m2) was durative transfused during the normalization window of the first chemoradiotherapy cycle(days -5～-1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar for two cycles
Description: Endostar(15mg/m2) was durative transfused during the normalization window of the first and the second chemoradiotherapy cycles(days -5～-1 and 24～28).
Study: NCT01138995

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ness L300
Description: The Ness L300 delivers functional electrical stimulation (FES), which improves gait function, stroke-specific quality of life, functionality, and safety for persons with stroke.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ankle-foot orthosis
Description: The Control Group will walk with a usual ankle-foot orthosis (AFO).
Study: NCT00923481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib disodium
Description: 200 mg BID was the administered dose for the initial part of the study and then a phase I dose escalation was added with 100 mg as the starting dose.
Study: NCT01502228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150-Water
Description: Patients will be imaged immediately before, and between 14-28 days after initiation of Sunitinib therapy, in the single bed position using the Siemens Biograph 64 TruePoint system located in the clinical facilities of the I.U. Cancer Center. Administer 15O-water at 50 mCi/dose, IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 62Cu-ethylglyoxal bis
Description: Imaging with 62Cu-ETS will be done immediately following imaging with 150-water. Patients will be imaged immediately before, and between 14-28 days after, initiation of Sunitinib therapy using the Siemens Biograph 64 TruePoint system located in the clinical facilities of the I.U. Cancer Center. Administer 62Cu-ETS in the range of 20-25 mCi/Dose, IV.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: PET Scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Study: NCT00719355

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking with poles
Description: Patients walked with poles, 20-45 minutes, 3 times/week for 24 weeks.
Study: NCT03500302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Evolocumab sq once a month for a total of two doses
Study: NCT03420456

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Light Therapy
Description: Transcranial light therapy penetrates the skin and brain using light energy; this makes transcranial light therapy noninvasive. Transcranial light therapy may activate under-stimulated brain regions.
Study: NCT02354040

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Talking Rx
Description: For patients in the intervention group, the physician written prescription for anti-platelet and statin will be transferred on an OMR sheet and will be scanned. The information on the prescription (dose, name of the medication, duration, route or any other special instruction) will be sent to the patients via a text and a voice SMS (in Urdu language). The patients also receive an individualized code that helps them request for repeated reminders for their medication timings. However, a weekly medication reminder SMS will be sent to the patients in the intervention arm.
Study: NCT03351426

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Transcranial Direct Current Stimulation (tDCS) is a noninvasive form of neuromodulation that uses constant, low-intensity direct current delivered via electrodes that are placed on the head.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Transcranial Direct Current Stimulation (tDCS) is a noninvasive form of neuromodulation that uses constant, low-intensity direct current delivered via electrodes that are placed on the head.
Study: NCT04669275

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Counselıng
Description: Telephone counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Counselıng
Description: Telephone counseling
Study: NCT03346109

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: medial group retropharyngeal node（MRLN） sparing
Description: Patients in MRLN sparing group will not routinely receive MRLN irradiation; while patients in MRLN prophylactic irradiation group will always receive MRLN irradiation to 56Gy/33Fr.
Study: NCT02219477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir
Description: tablet; paritaprevir co-formulated with ritonavir and ombitasvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir
Description: tablet; paritaprevir co-formulated with ritonavir and ombitasvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir
Description: tablet; paritaprevir co-formulated with ritonavir and ombitasvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasabuvir
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasabuvir
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: tablet
Study: NCT02630576

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular stimulation
Description: Single twitch and train-of-four stimulation protocols will be performed at the randomised side with growing current intensity

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular stimulation
Description: Single twitch and train-of-four stimulation protocols will be performed at the randomised side with growing current intensity

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular stimulation
Description: Single twitch and train-of-four stimulation protocols will be performed at the randomised side with growing current intensity

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular stimulation
Description: Single twitch and train-of-four stimulation protocols will be performed at the randomised side with growing current intensity
Study: NCT00607321

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Bifurcation Stent System
Description: Percutaneous Coronary Stenting
Study: NCT03415646

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: erector spinae plane block with double level injection will be administered before the surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Morphine patient controlled analgesia device
Description: 24 hour morphine consumption will be recorded

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Intravenous Morphine patient controlled analgesia device
Description: 24 hour morphine consumption will be recorded
Study: NCT02623569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Description: Not Provided

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol
Description: Not Provided